Physician profile
Neil J Gonter
NPI 1760465579
$4,237.00
in general payments reported to CMS, 2019-2025
20 companies · $659 in 2025
The $659 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,961 · 2020: $51.49 · 2021: $41.87 · 2022: $85.87 · 2023: $146 · 2024: $292 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,863.70 | 2019-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $430.05 | 2021-2025 | |
| Amgen INC. | $246.39 | 2020-2025 | Krystexxa, Tavneos |
| Fresenius Kabi USA, LLC | $161.69 | 2023-2025 | Idacio |
| Abbvie INC. | $96.47 | 2022-2025 | |
| Genentech USA, INC. | $77.25 | 2019 | |
| Janssen Biotech, INC. | $58.49 | 2019-2025 | Tremfya |
| Medexus Pharma, INC. | $39.04 | 2019 | |
| Invivyd INC | $37.11 | 2025 | Pemgarda |
| Radius Health, INC. | $34.07 | 2024-2025 | Tymlos |
| Pfizer INC. | $26.27 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $25.16 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $23.76 | 2022 | |
| Tersera Therapeutics LLC | $22.75 | 2022 | |
| Depuy Synthes Sales INC. | $20.91 | 2024 | Monovisc |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.56 | 2025 | Ofev |
| Glaxosmithkline, LLC. | $14.76 | 2024 | Benlysta |
| Sanofi-Aventis U.S. LLC | $14.61 | 2021 | |
| Ucb, INC. | $14.48 | 2024 | Bimzelx |
| Octapharma USA, INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Gonter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.